Evidence map›Paper›PMID 34237029›Full record

ArticleThe Journal of clinical investigation2021

A metabolic inhibitor arms macrophages to kill intracellular fungal pathogens by manipulating zinc homeostasis.

Diego Cp Rossi, Julio A Landero Figueroa, William R Buesing, Kathleen Candor, Logan T Blancett, Heather M Evans, Rena Lenchitz, Bradford L Crowther, Waleed Elsegeiny, Peter R Williamson and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Metals at the Host-Fungal Pathogen Battleground.Annual review of microbiology · 2024
    Review
  5. Article
  6. Review
  7. Utilization of amSphere · 2024
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Diego Cp RossiDivision of Infectious Diseases, College of Medicine and.
Julio A Landero FigueroaUniversity of Cincinnati/Agilent Technologies Metallomics Center of the Americas, Department of Chemistry, University of Cincinnati, Cincinnati, Ohio, USA.
William R BuesingDivision of Infectious Diseases, College of Medicine and.
Kathleen CandorDivision of Infectious Diseases, College of Medicine and.
Logan T BlancettDivision of Infectious Diseases, College of Medicine and.
Heather M EvansDivision of Infectious Diseases, College of Medicine and.
Rena LenchitzDivision of Infectious Diseases, College of Medicine and.
Bradford L CrowtherDivision of Infectious Diseases, College of Medicine and.
Waleed ElsegeinyLaboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
Peter R WilliamsonLaboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
Jan RuppDepartment of Infectious Diseases and Microbiology, German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany.
George S DeepeDivision of Infectious Diseases, College of Medicine and.
Agilent Technologies (United States) · USNational Institute of Allergy and Infectious Diseases · USGerman Center for Infection Research · DEUniversity of Cincinnati Medical Center · US

Funding

Molecular Pathobiology of Cryptococcus neoformansZIAAI001123 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WILLIAMSON, PETER · 2010 to 2025
$10.4M
GM-CSF-Induced Metal Sequestration and HistoplasmaR01AI106269 · NIAID · UNIVERSITY OF CINCINNATI · PI DEEPE, GEORGE S. · 2013 to 2022
$5.0M
HIF Regulation of Histoplasma PathogenesisR01AI133797 · NIAID · UNIVERSITY OF CINCINNATI · PI DEEPE, GEORGE S. · 2018 to 2022
$2.0M
NIAID NIH HHS R01 AI106269NIAID NIH HHS R01 AI133797
6 · The paper itself

Abstract

Macrophages deploy numerous strategies to combat invasion by microbes. One tactic is to restrict acquisition of diverse nutrients, including trace metals, a process termed nutritional immunity. Intracellular pathogens adapt to a resource-poor environment by marshaling mechanisms to harvest nutrients. Carbon acquisition is crucial for pathogen survival; compounds that reduce availability are a potential strategy to control intracellular replication. Treatment of macrophages with the glucose analog 2-deoxy-D-glucose (2-DG) armed phagocytes to eliminate the intracellular fungal pathogen Histoplasma capsulatum in vitro and in vivo. Killing did not rely on altering access to carbon-containing molecules or changes in ATP, ER stress, or autophagy. Unexpectedly, 2-DG undermined import of exogenous zinc into macrophages, decreasing the quantity of cytosolic and phagosomal zinc. The fungus perished as a result of zinc starvation. This change in metal ingress was not ascribed to a defect in a single importer; rather, there was a collective impairment in transporter activity. This effect promoted the antifungal machinery of macrophages and expanded the complexity of 2-DG activities far beyond manipulating glycolysis. Mechanistic metabolic studies employing 2-DG will have to consider its effect on zinc transport. Our preclinical data support consideration of this agent as a possible adjunctive therapy for histoplasmosis.

Indexed as

AnimalsAntifungal AgentsAntimetabolitesAutophagyBiological Transport, ActiveDeoxyglucoseFemaleGlycolysisHistoplasmaHomeostasisHumansIn Vitro TechniquesMacrophagesMaleMiceMice, Inbred C57BLAntifungal AgentsAntimetabolitesDeoxyglucoseZincFungal infectionsInfectious diseaseMacrophagesMicrobiology

Identifiers

PMID34237029
PMCPMC8363289
OpenAlexW3178371357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.